Welcome to our dedicated page for Apellis Pharmace SEC filings (Ticker: APLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Apellis Pharmaceuticals, Inc. (APLS) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a commercial-stage biopharmaceutical issuer listed on the Nasdaq Global Select Market, Apellis uses filings such as Forms 10-K, 10-Q, 8-K, and others to report on its business, financial condition, risk factors, and material events related to its complement-based therapies SYFOVRE and EMPAVELI/Aspaveli.
In these filings, investors can review detailed information on revenue from SYFOVRE and EMPAVELI, research and development spending for ophthalmology and rare disease programs, and the status of key clinical trials such as GALE and VALIANT. Risk factor and management discussion sections typically describe the scientific and regulatory considerations associated with targeting C3 in geographic atrophy, C3 glomerulopathy, primary IC-MPGN, and paroxysmal nocturnal hemoglobinuria.
Current reports on Form 8-K, such as the Royalty Buy-Down Agreement with Swedish Orphan Biovitrum AB (Sobi), document material definitive agreements that affect Apellis’ economics, including ex-U.S. royalty structures for Aspaveli and related financing consents. These filings help clarify how collaborations and capital arrangements support the company’s commercialization and pipeline strategy.
On Stock Titan, Apellis filings are updated in near real time as they are posted to EDGAR. AI-powered summaries highlight key points from lengthy documents, helping readers quickly understand topics like royalty arrangements, cash runway, product revenue trends, and major clinical or regulatory milestones. Users can also review Forms 4 and other insider transaction reports to monitor trading activity by Apellis directors and executives, alongside proxy and governance disclosures that describe compensation and board oversight. This page is a central resource for analyzing the regulatory record behind APLS stock.
Apellis Pharmaceuticals has a shareholder planning to sell 2618 shares of common stock under Rule 144. The shares are to be sold through Fidelity Brokerage Services LLC, with an aggregate market value of 58086.09, on or about 01/13/2026 on the NASDAQ exchange. The filing notes that 126525218 shares of the issuer’s stock are outstanding. The 2618 shares being sold were acquired on 01/12/2026 through restricted stock vesting from the issuer as compensation, indicating they are newly vested shares now eligible for resale under Rule 144.
Apellis Pharmaceuticals shareholder files notice to sell restricted stock. A holder of Apellis common shares filed a Form 144 to potentially sell 873 shares of common stock through Fidelity Brokerage Services LLC on or about 01/13/2026, with the shares listed on NASDAQ. The shares have an aggregate market value of $19,369.43, compared with 126,525,218 common shares outstanding. These securities were acquired on 01/12/2026 via restricted stock vesting from the issuer as compensation, with payment also dated 01/12/2026.
Apellis Pharmaceuticals insider David O. Watson filed a notice of proposed sale of 5,780 common shares under Rule 144. The shares are expected to be sold through Fidelity Brokerage Services on NASDAQ around 01/13/2026, with an indicated aggregate market value of 128,242.01. The filing notes that 126,525,218 common shares were outstanding.
The 5,780 shares were acquired on 01/12/2026 through restricted stock vesting from the issuer as compensation. The notice also lists prior sales by Watson over the past three months, including three separate sales of 5,000 common shares each on 10/16/2025, 11/17/2025, and 12/16/2025 with gross proceeds of 126,100.00, 100,300.00, and 122,450.00, respectively.
A shareholder filed a Rule 144 notice to sell 1,780 shares of common stock through Fidelity Brokerage Services LLC on or about 01/13/2026, with an indicated aggregate market value of 39,493.22. The planned sale is listed for trading on NASDAQ, and the table notes that there were 126,525,218 shares outstanding when the form was prepared.
The shares to be sold were acquired on 01/12/2026 via a restricted stock vesting transaction from the issuer, described as compensation. The signer represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
A shareholder of APLS filed a notice of proposed sale of common stock under Rule 144. The filing covers the potential sale of 2,277 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of $50,520.25, when 126,525,218 shares of the issuer’s common stock were outstanding. The shares to be sold were acquired from the issuer as restricted stock vesting on 01/12/2026 as compensation, with an approximate intended sale date of 01/13/2026 on the NASDAQ exchange.
A Form 144 notice was filed covering a planned sale of 10,186 shares of common stock, with an aggregate market value of $225,998.82. The shares are to be sold through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate sale date of 01/13/2026. The securities relate to an issuer with 126,525,218 shares outstanding. The seller acquired these shares on 01/12/2026 through restricted stock vesting from the issuer as compensation.
APLS insider Timothy E. Sullivan has filed a notice of proposed sale of restricted stock under Rule 144. The planned transaction covers 3,856 shares of common stock to be sold through Fidelity Brokerage Services LLC on or about 01/13/2026 on the NASDAQ, with an aggregate market value of 85,553.84 based on the figures disclosed.
The shares to be sold were acquired from the issuer on 01/12/2026 through restricted stock vesting as compensation, with full amount of 3,856 shares acquired and paid on that date. Over the prior three months, Sullivan sold 10,000 common shares on 10/21/2025 for gross proceeds of 280,300.00.
By signing the notice, the seller represents that he does not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed and acknowledges that intentional misstatements or omissions can constitute federal criminal violations.
Apellis Pharmaceuticals, Inc. furnished an update on its recent performance by issuing a press release with preliminary unaudited U.S. net product revenues for the fourth quarter and full year ended December 31, 2025. The update covers revenues for its products SYFOVRE and EMPAVELI, along with the company’s cash and cash equivalents as of December 31, 2025. These figures are management’s estimates, remain subject to completion of normal year-end closing procedures, and have not been audited or reviewed by the company’s independent registered public accounting firm. The press release containing the detailed numbers is included as an exhibit to this report.
Apellis Pharmaceuticals general counsel David O. Watson reported an insider equity transaction. On January 7, 2026, he exercised a stock option for 888 shares of Apellis common stock at an exercise price of $14.95 per share. Following this option exercise, he directly holds 104,618 shares of Apellis common stock.
The filing also lists indirect holdings. A custodial account for his minor children holds 10,000 shares. In addition, 50,136 shares are held by The David O. Watson Irrevocable Trust of 2023, for which William Zorn serves as trustee; Watson disclaims beneficial ownership of those trust shares except to the extent of his pecuniary interest.
Apellis Pharmaceuticals Chief Medical Officer Caroline Baumal reported a sale of common stock. On January 5, 2026, she sold 3,020 shares of Apellis Pharmaceuticals, Inc. common stock at a price of $25.5287 per share. According to the disclosure, these shares were sold to cover tax withholding obligations arising from Restricted Stock Units that were released on January 3, 2026, rather than as a discretionary open-market sale. Following this transaction, Baumal beneficially owns 91,206 shares of common stock directly, which includes 925 shares acquired through an employee stock purchase plan on October 31, 2025.